Drug and Alcohol Dependence

Article	Citations
The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017	251
Alcohol and other substance use during the COVID-19 pandemic: A systematic review	226
Alcohol use and mental health during COVID-19 lockdown: A cross-sectional study in a sample of UK adults	164
Xylazine spreads across the US: A growing component of the increasingly synthetic and polysubstance overdose crisis	159
Adverse childhood experiences (ACEs) and substance use disorder (SUD): A scoping review	125
Steep increases in fentanyl-related mortality west of the Mississippi River: Recent evidence from county and state surveillance	108
Factors associated with drinking behaviour during COVID-19 social distancing and lockdown among adults in the UK	103
The early impact of COVID-19 on the incidence, prevalence, and severity of alcohol use and other drugs: A systematic review	99
The role of stigma in U.S. primary care physicians’ treatment of opioid use disorder	88
Contingency management for the treatment of methamphetamine use disorder: A systematic review	85
Emotion regulation and substance use: A meta-analysis	84
Fentanyl and fentanyl analogs in the illicit stimulant supply: Results from U.S. drug seizure data, 2011–2016	78
Patterns of substance use among adolescents: A systematic review	76
Trends in seizures of powders and pills containing illicit fentanyl in the United States, 2018 through 2021	75
Barriers to accessing opioid substitution treatment for opioid use disorder: A systematic review from the client perspective	73
Evaluating the impact of COVID-19: A cohort comparison study of drug use and risky sexual behavior among sexual minority men in the U.S.A.	68
Socially-supportive norms and mutual aid of people who use opioids: An analysis of Reddit during the initial COVID-19 pandemic	68
Transition from injecting opioids to smoking fentanyl in San Francisco, California	65
Prevalence and modes of cannabis use among youth in Canada, England, and the US, 2017 to 2019	65
The Opioid-overdose Reduction Continuum of Care Approach (ORCCA): Evidence-based practices in the HEALing Communities Study	63
The intersection of gender and drug use-related stigma: A mixed methods systematic review and synthesis of the literature	62
Pharmacy-related buprenorphine access barriers: An audit of pharmacies in counties with a high opioid overdose burden	59
Addressing opioid overdose deaths: The vision for the HEALing communities study	56
Identifying individuals with opioid use disorder: Validity of International Classification of Diseases diagnostic codes for opioid use, dependence and abuse	55
The HEALing (Helping to End Addiction Long-term SM) Communities Study: Protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through implementation of an inte	54

Prevalence of mental disorders among people with opioid use disorder: A systematic review and meta-analysis	53
Drug overdose deaths involving cocaine and psychostimulants with abuse potential among racial and ethnic groups – United States, 2004–2019	52
Adolescent drug use before and during U.S. national COVID-19 social distancing policies	50
Opioid-related overdose mortality in the era of fentanyl: Monitoring a shifting epidemic by person, place, and time	49
Community engagement to implement evidence-based practices in the HEALing communities study	49
Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder	49
Health communication campaigns to drive demand for evidence-based practices and reduce stigma in the HEALing communities study	48
Anabolic androgenic steroids, antisocial personality traits, aggression and violence	48
A randomized controlled trial of a therapeutic relational agent for reducing substance misuse during the COVID-19 pandemic	48
Growing racial/ethnic disparities in buprenorphine distribution in the United States, 2007-2017	46
Racial inequity in medication treatment for opioid use disorder: Exploring potential facilitators and barriers to use	46
Racial/ethnic differences in prescription opioid misuse and heroin use among a national sample, 1999–2018	46
Barriers and facilitators to a novel low-barrier hydromorphone distribution program in Vancouver, Canada: a qualitative study	45
Joint perceptions of the risk and availability of Cannabis in the United States, 2002-2018	45
Alcohol and substance use in pregnancy during the COVID-19 pandemic	44
The health and social consequences during the initial period of the COVID-19 pandemic among current and former people who inject drugs: A rapid phone survey in Baltimore, Maryland	44
Lyophilized Kratom Tea as a Therapeutic Option for Opioid Dependence	43
Therapeutic benefit with caveats?: Analyzing social media data to understand the complexities of kratom use	43
The continued rise of methamphetamine use among people who use heroin in the United States	41
The naloxone delivery cascade: Identifying disparities in access to naloxone among people who inject drugs in Los Angeles and San Francisco, CA	41
Trends in stimulant dispensing by age, sex, state of residence, and prescriber specialty — United States, 2014–2019	41
Impact of state-level cannabis legalization on poly use of alcohol and cannabis in the United States, 2004–2017	41
Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients’ experiences in Australia	41
Community dashboards to support data-informed decision-making in the HEALing communities study	41
The prevalence, child characteristics, and maternal risk factors for the continuum of fetal alcohol spectrum disorders: A sixth population-based study in the same South African community	40
A systematic review and meta-analysis of medications for stimulant use disorders in patients with co-occurring opioid use disorders	40
Prevalence of childhood maltreatment among people with opioid use disorder: A systematic review and meta-analysis	39
Effects of multiple adverse childhood experiences on substance use in young adults: A review of the literature	39
Conceptualizing stigma in contexts of pregnancy and opioid misuse: A qualitative study with women and healthcare providers in Ohio	38
Substance use disorders and risk of severe maternal morbidity in the United States	38
Age and gender-specific hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington	37
Using machine learning for real-time BAC estimation from a new-generation transdermal biosensor in the laboratory	37
Quantity and frequency of cannabis use in relation to cannabis-use disorder and cannabis-related problems	37
Prevalence and charges of opioid-related visits to U.S. emergency departments	37
Impacts of the COVID-19 pandemic on healthcare access among patients receiving medication for opioid use disorder	37
Opioid use disorder treatment for people experiencing homelessness: A scoping review	36
Genomic relationships across psychiatric disorders including substance use disorders	36
Racial/ethnic disparities in the use of medications for opioid use disorder (MOUD) and their effects on residential drug treatment outcomes in the US	36
Evaluation of an emergency safe supply drugs and managed alcohol program in COVID-19 isolation hotel shelters for people experiencing homelessness	35
LSD use in the United States: Trends, correlates, and a typology of us	35
“I felt like I had a scarlet letter”: Recurring experiences of structural stigma surrounding opioid tapers among patients with chronic, non-cancer pain	35
Associations between vaping and Covid-19: Cross-sectional findings from the HEBECO study	35
Longitudinal associations with alcohol consumption during the first COVID-19 lockdown: Associations with mood, drinking motives, context of drinking, and mental health	34
Drug checking identifies counterfeit alprazolam tablets	34
Transgender-related discrimination and substance use, substance use disorder diagnosis and treatment history among transgender adults	32
Knowledge, preparedness, and compassion fatigue among law enforcement officers who respond to opioid overdose	32
Comparing actual and forecasted numbers of unique patients dispensed select medications for opioid use disorder, opioid overdose reversal, and mental health, during the COVID-19 pandemic, United State	32
The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD	32
Marijuana, but not alcohol, use frequency associated with greater loneliness, psychological distress, and less flourishing among young adults	32
The cost of opioid use disorder and the value of aversion	31

The Association between Opioid Discontinuation and Heroin Use: A Nested Case-Control Study	31
Trust in a COVID-19 vaccine among people with substance use disorders	31
Frequency of cannabis use during pregnancy and adverse infant outcomes, by cigarette smoking status – 8 PRAMS states, 2017	30
Prevalence of substance use and substance-related disorders among US Veterans Health Administration patients	30
Shifts in drug seizures in the United States during the COVID-19 pandemic	30
Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort	30
Legality of drug checking equipment in the United States: A systematic legal analysis	30
Results from a mobile drug checking pilot program using three technologies in Chicago, IL, USA	29
Use of telemedicine for opioid use disorder treatment – Perceptions and experiences of opioid use disorder clinicians	29
Structural and functional brain recovery in individuals with substance use disorders during abstinence: A review of longitudinal neuroimaging studies	29
LGBTQ state policies: A lever for reducing SGM youth substance use and bullying	29
Healthcare stigma and HIV risk among rural people who inject drugs	29
Characteristics and correlates of U.S. clinicians prescribing buprenorphine for opioid use disorder treatment using expanded authorities during the COVID-19 pandemic	28
Nicotine formulations impact reinforcement-related behaviors in a mouse model of vapor self-administration	28
Pregnant people’s experiences discussing their cannabis use with prenatal care providers in a state with legalized cannabis	28
Identifying risk-thresholds for the association between frequency of cannabis use and development of cannabis use disorder: A systematic review and meta-analysis	28
How prescription drug monitoring programs influence clinical decision-making: A mixed methods systematic review and meta-analysis	28
Effectiveness of peer recovery support services on stages of the opioid use disorder treatment cascade: A systematic review	28
Harm reduction and health services provided by syringe services programs in 2019 and subsequent impact of COVID-19 on services in 2020	28
Model and approach for assessing implementation context and fidelity in the HEALing Communities Study	28
Changes in alcohol use since the onset of COVID-19 are associated with psychological distress among sexual and gender minority university students in the U.S	27
Using ICD-10-CM codes to detect illicit substance use: A comparison with retrospective self-report	27
Cannabis-related diagnosis in pregnancy and adverse maternal and infant outcomes	27
Mental and physical health in family members of substance users: A scoping review	27
Awareness, use and perceptions of cigarillos, heated tobacco products and nicotine pouches: A survey among Dutch adolescents and adults	27
Overdose deaths involving psychostimulants with abuse potential, excluding cocaine: State-level differences and the role of opioids	27
Treatment provider perceptions of take-home methadone regulation before and during COVID-19	27
Cannabis legalization and cannabis use, daily cannabis use and cannabis-related problems among adults in Ontario, Canada (2001–2019)	27
Impact of cannabis legalization in the United States on trends in cannabis use and daily cannabis use among individuals who smoke cigarettes	27
Frequent teenage cannabis use: Prevalence across adolescence and associations with young adult psychopathology and functional well-being in an urban cohort	27
Use frequency and symptoms of nicotine dependence among adolescent E-cigarette users: Comparison of JUUL and Non-JUUL users	26
Cannabis use disorder and dissociation: A report from a prospective first-episode psychosis study	26
Adolescent nicotine and marijuana vaping activity and the use of other illicit substances	26
How much and how fast: Alcohol consumption patterns, drinking-episode affect, and next-day consequences in the daily life of underage heavy drinkers	26
Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states	26
Perceived risk, attitudes, and behavior of cigarette smokers and nicotine vapers receiving buprenorphine treatment for opioid use disorder during the COVID-19 pandemic	25
COVID-19 vaccine trust among clients in a sample of California residential substance use treatment programs	25
Systematic review and meta-analysis of socio-cognitive and socio-affective processes association with adolescent substance use	25
Primary care physicians’ preparedness to treat opioid use disorder in the United States: A cross-sectional survey	25
Quarterly trends in past-month cannabis use in the United States, 2015-2019	25
Use of highly-potent cannabis concentrate products: More common in U.S. states with recreational or medical cannabis laws	25
A pilot feasibility study of a behavioral intervention for nicotine vaping cessation among young adults delivered via telehealth	25
Estimating the community prevalence, child traits, and maternal risk factors of fetal alcohol spectrum disorders (FASD) from a random sample of school children	25
Do out-of-pocket costs influence retention and adherence to medications for opioid use disorder?	24
Fentanyl causes naloxone-resistant vocal cord closure: A platform for testing opioid overdose treatments	24
Associations of alcohol use, mental health and socioeconomic status in England: Findings from a representative population survey	24
Recent trends and associated factors of amphetamine-type stimulant overdoses in emergency departments	24
Adherence to buprenorphine: An analysis of prescription drug monitoring program data	24
Test-retest reliability of DSM-5 substance disorder measures as assessed with the PRISM-5, a clinician-administered diagnostic interview	24
Contrasting effects of adolescent and early-adult ethanol exposure on prelimbic cortical pyramidal neurons	24
Review of sexualized drug use associated with sexually transmitted and blood-borne infections in gay, bisexual and other men who have sex with men	24
Canada’s cannabis legalization and drivers’ traffic-injury presentations to emergency departments in Ontario and Alberta, 2015-2019	24
Impact of an unsanctioned safe consumption site on criminal activity, 2010–2019	24
Testing the drug use and condomless anal sex link among sexual minority men: The predictive utility of marijuana and interactions with relationship status	23
Psychosocial and health problems associated with alcohol use disorder and cannabis use disorder in U.S. adults	23
Victim and perpetrator characteristics in alcohol/drug-involved sexual violence victimization in the U.S	23
Racial/ethnic discrimination and alcohol use disorder severity among United States adults	23
Effects of fentanyl on acute locomotor activity, behavioral sensitization, and contextual reward in female and male rats	23
Substance use patterns in 9-10 year olds: Baseline findings from the adolescent brain cognitive development (ABCD) study	23
Addressing long overdue social and structural determinants of the opioid epidemic	23
Gender, employment, and continuous pandemic as predictors of alcohol and drug consumption during the COVID-19	23
Tobacco and marijuana co-use in a cohort of young adults: Patterns, correlates and reasons for co-use	23
What is associated with the increased frequency of heavy episodic drinking during the COVID-19 pandemic? Data from the PAHO regional web-based survey	23
Between- and within-group effects of alcohol and cannabis co-use on AUD/CUD in the NSDUH 2002–2019	23
Prospective associations of e-cigarette use with cigarette, alcohol, marijuana, and nonmedical prescription drug use among US adolescents	23
Disparities in alcohol use and heavy episodic drinking among bisexual people: A systematic review, meta-analysis, and meta-regression	23
Nicotine dependence symptoms in U.S. youth who use JUUL E-cigarettes	23
Robustness of estimated access to opioid use disorder treatment providers in rural vs. urban areas of the United States	23
Liver injury associated with kratom, a popular opioid-like product: Experience from the U.S. drug induced liver injury network and a review of the literature	23
Evaluating equity in community-based naloxone access among racial/ethnic groups in Massachusetts	22
The impact of the national stay-at-home order on emergency department visits for suspected opioid overdose during the first wave of the COVID-19 pandemic	22
Evaluation of an emergency department-based opioid overdose survivor intervention: Difference-in-difference analysis of electronic health record data to assess key outcomes	22
Measurement invariance and psychometric properties of Perceived Stigma toward People who use Substances (PSPS) among three types of substance use disorders: Heroin, amphetamine, and alcohol	22
Association between observing peers vaping on campus and E-cigarette use and susceptibility in middle and high school students	22
Cannabidiol (CBD) product contamination: Quantitative analysis of Δ9-tetrahydrocannabinol (Δ9-THC) concentrations found in commercially available CBD products	22
COVID-19 survey among people who use drugs in three cities in Norway	22
Race, pain, and opioids among patients with chronic pain in a safety-net health system	22
Abuse liability assessment of the JUUL system in four flavors relative to combustible cigarette, nicotine gum and a comparator electronic nicotine delivery system among adult smokers	22
Prevalence of new psychoactive substances (NPS) in Brazil based on oral fluid analysis of samples collected at electronic music festivals and parties	22
Nicotine/tobacco use disparities among transgender and gender diverse adults: Findings from wave 4 PATH data	22

Retail availability and legal purchases of dried flower in Canada post-legalization	22
Agreement between DSM-5 and DSM-IV measures of substance use disorders in a sample of adult substance users	22
Variability in the unregulated opioid market in the context of extreme rates of overdose	22
Genome-wide association analysis of opioid use disorder: A novel approach using clinical data	21
Effects of acute exercise on craving, mood and anxiety in non-treatment seeking adults with alcohol use disorder: An exploratory study	21
The impact of COVID-19 on opioid treatment programs in the United States	21
Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: Results from a multisite trial of buprenorphine-naloxone and methadone	21
Vaping identity in adolescent e-cigarette users: A comparison of norms, attitudes, and behaviors	21
Medical provider stigma experienced by people who use drugs (MPS-PWUD): Development and validation of a scale among people who currently inject drugs in New York City	21
Medications for opioid use disorder among American Indians and Alaska natives: Availability and use across a national sample	21
Age groups differences in the prevalence and popularity of individual tobacco product use in young adult and adult marijuana and tobacco co-users and tobacco-only users: Findings from Wave 4 of the po	21
Trends in various e-cigarette devices used by high school adolescents from 2017-2019	21
Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder	21
Trajectories of alcohol use and problems during the COVID-19 pandemic: The role of social stressors and drinking motives for men and women	21
Alcohol craving and withdrawal at treatment entry prospectively predict alcohol use outcomes during outpatient treatment	21
Trends and characteristics of cannabis-associated emergency department visits in the United States, 2006–2018	21
Cannabis use disorder treatment use and perceived treatment need in the United States: Time trends and age differences between 2002 and 2019	21
Minority stress and drug use among transgender and gender diverse adults: A daily diary study	21
Utilizing telemedicine during COVID-19 pandemic for a low-threshold, street-based buprenorphine program	21
Changes in opioid prescribing after implementation of mandatory registration and proactive reports within California’s prescription drug monitoring program	20
Chemsex practices and pre-exposure prophylaxis (PrEP) trajectories among individuals consulting for PrEP at a large sexual health clinic in Montréal, Canada (2013-2020)	20
Repeated morphine exposure activates synaptogenesis and other neuroplasticity-related gene networks in the dorsomedial prefrontal cortex of male and female rats	20
Neurocognitive impairments and brain abnormalities resulting from opioid-related overdoses: A systematic review	20
Polysubstance use among youth experiencing homelessness: The role of trauma, mental health, and social network composition	20
Use of anabolic-androgenic steroids and other substances prior to and during imprisonment - Results from the Norwegian Offender Mental Health and Addiction (NorMA) study	20
Predictors of vaping marijuana initiation among US adolescents: Results from the Population Assessment of Tobacco and Health (PATH) study Wave 3 (2015–2016) and Wave 4 (2016–2018)	20
Prevalence and minority-stress correlates of past 12-month prescription drug misuse in a national sample of transgender and gender nonbinary adults: Results from the U.S. Transgender Survey	20
The use of person-centered language in scientific research articles focusing on alcohol use disorder	20
Barriers and facilitators to PDMP IS Success in the US: A systematic review	20
Alcohol consumption and incidence of sleep disorder: A systematic review and meta-analysis of cohort studies	20
Chemsex and chemsex associated substance use among men who have sex with men in Asia: A systematic review and meta-analysis	20
Structural racism and violence as social determinants of health: Conceptual, methodological and intervention challenges	20
“That person stopped being human”: Intersecting HIV and substance use stigma among patients and providers in South Africa	20
Harm reduction outcomes and practices in Housing First: A mixed-methods systematic review	20
Predictors of marijuana vaping onset and escalation among young adults	19
Factors associated with early and later dropout from methadone maintenance treatment in specialist addiction clinics: a six-year cohort study using proportional hazards frailty models for recurrent tr	19
Sociodemographic changes in emergency department visits due to alcohol during COVID-19	19
Knowledge, attitudes, and prescribing patterns of cannabis and cannabinoid-containing medicines among European healthcare workers: a systematic literature review	19
Sexual minority tobacco use disparities across adolescence and the transition to young adulthood	19
Health, social and legal outcomes of individuals with diagnosed or at risk for fetal alcohol spectrum disorder: Canadian example	19
The impact of menthol flavoring in combusted tobacco on alternative product purchasing: A pilot study using the Experimental Tobacco Marketplace	19
Trends in homelessness and injection practices among young urban and suburban people who inject drugs: 1997-2017	19
Prevalence, risk and protective factors of alcohol use disorder during the COVID-19 pandemic in U.S. military veterans	19
Cannabis use and misuse in the year following recreational cannabis legalization in Canada: A longitudinal observational cohort study of community adults in Ontario	19
US drug overdose mortality rose faster among hispanics than non-hispanics from 2010 to 2021	19
Bridge clinic implementation of “72-hour rule” methadone for opioid withdrawal management: Impact on opioid treatment program linkage and retention in care	19
Disparities in substance use disorder treatment use and perceived need by sexual identity and gender among adults in the United States	18
Using community engagement to implement evidence-based practices for opioid use disorder: A data-driven paradigm & systems science approach	18
Socio-ecological and pharmacy-level factors associated with naloxone stocking at standing-order naloxone pharmacies in New York City	18
Adjunct interventions to standard medical management of buprenorphine in outpatient settings: A systematic review of the evidence	18
Impact of polysubstance use on high-sensitivity cardiac troponin I over time in homeless and unstably housed women	18
Substance use disorders and COVID-19: An analysis of nation-wide Veterans Health Administration electronic health records	18
Risk of cardiovascular diseases in relation to substance use disorders	18
Buprenorphine implementation at syringe service programs following waiver of the Ryan Haight Act in the United States	18
Opioid-related deaths before and after COVID-19 stay-at-home orders in Los Angeles County	18
Concomitant drugs with buprenorphine user deaths	18
Mirtazapine for the treatment of amphetamine and methamphetamine use disorder: A systematic review and meta-analysis	18
Quetiapine treatment for cannabis use disorder	18
The impact of psychiatric comorbidity on treatment discontinuation among individuals receiving medications for opioid use disorder	18
Relations between impulsive personality traits, alcohol and cannabis co-use, and negative alcohol consequences: A test of cognitive and behavioral mediators	18
Introducing NIDA’s New National Drug Early Warning System	18
Using TikTok in recovery from substance use disorder	18
Lifetime marijuana use and epigenetic age acceleration: A 17-year prospective examination	17
When national drug surveys “take too long”: An examination of who is at risk for survey fatigue	17
Validation of a lateral flow chromatographic immunoassay for the detection of fentanyl in drug samples	17
Drug use-related stigma, safer injection norms, and hepatitis C infection among a network-based sample of young people who inject drugs	17
The contribution of methamphetamine use to crime: Evidence from Australian longitudinal data	17
Gender differences in the prevalence of heroin and opioid analgesic misuse in the United States, 2015–2019	17
Maintaining recovery from alcohol use disorder during the COVID-19 pandemic: The importance of recovery capital	17
Electronic nicotine delivery systems use predicts transitions in cigarette smoking among young adults	17
Efficacy of ketamine intervention to decrease alcohol use, cravings, and withdrawal symptoms in adults with problematic alcohol use or alcohol use disorder: A systematic review and comprehensive analy	17
Age-specific treatment effects of orexin/hypocretin-receptor antagonism on methamphetamine-seeking behavior	17
Chemokines, cytokines and substance use disorders	17
Effect of alcohol interventions on suicidal ideation and behaviour: A systematic review and meta-analysis	17
Prescription fill patterns for benzodiazepine and opioid drugs during the COVID-19 pandemic in the United States	17
County-level predictors of US drug overdose mortality: A systematic review	17
Examining the impact of the first wave of COVID-19 and associated control measures on interventions to prevent blood-borne viruses among people who inject drugs in Scotland: an interrupted time series	17
Effects of daily Δ9-Tetrahydrocannabinol (THC) alone or combined with cannabidiol (CBD) on cognition-based behavior and activity in adolescent nonhuman primates	17
Salivary measurement and mindfulness-based modulation of prescription opioid cue-reactivity	17
Broadening access to naloxone: Community predictors of standing order naloxone distribution in Massachusetts	17
Factors associated with methamphetamine withdrawal symptoms among people who inject drugs	17
Detachment, peer pressure, and age of first substance use as gateways to later substance use	17
Tramadol non-medical use in Four European countries: A comparative analysis	17
Associations of cannabis retail outlet availability and neighborhood disadvantage with cannabis use and related risk factors among young adults in Washington State	17
A synthetic opioid vaccine attenuates fentanyl-vs-food choice in male and female rhesus monkeys	17
Transitions in care between hospital and community settings for individuals with a substance use disorder: A systematic review	17
Adolescent depression symptoms and e-cigarette progression	17
Computer- vs. nurse practitioner-delivered brief intervention for adolescent marijuana, alcohol, and sex risk behaviors in school-based health centers	17
Validation and threshold identification of a prescription drug monitoring program clinical opioid risk metric with the WHO alcohol, smoking, and substance involvement screening test	16
Hnrnph1 is a novel regulator of alcohol reward	16
Bidirectional associations between e-cigarette use and alcohol use across adolescence	16
Wearable biosensors have the potential to monitor physiological changes associated with opioid overdose among people who use drugs: A proof-of-concept study in a real-world setting	16
Impulsivity and craving in subjects with opioid use disorder on methadone maintenance treatment	16
Characteristics of post-overdose public health-public safety outreach in Massachusetts	16
Epigenome-wide study of brain DNA methylation following acute opioid intoxication	16